Observational study reveals associations between CSF biomarkers and MRI markers in probable cerebral amyloid angiopathy, suggesting direct tracking of vascular amyloid burden.
Key Points
To determine the relationship between cerebrospinal fluid amyloid biomarkers and MRI markers of hemorrhagic and nonhemorrhagic disease severity in patients diagnosed with probable cerebral amyloid angiopathy.
Evaluated patients diagnosed with probable cerebral amyloid angiopathy based on standard MRI-defined Boston criteria.
Assessed cerebrospinal fluid levels of β-amyloid 1–42 (Aβ42) and β-amyloid 1–40 (Aβ40) in relation to neuroimaging markers of vascular damage.
Analyzed associations between fluid amyloid concentrations and MRI markers of hemorrhagic and nonhemorrhagic disease severity (numerical effect sizes and p-values were not provided in the abstract).
Positioned CSF Aβ40 and Aβ42 as direct indicators of vascular amyloid burden that capture disease pathology earlier than downstream structural MRI damage.